Appili Therapeutics Receives Eligibility for DTC Trading in the U.S.
11 Agosto 2020 - 9:57AM
Business Wire
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company
or Appili), a biopharmaceutical company developing anti-infective
drug candidates, today announced that its common shares listed in
the United States, under the symbol APLIF, are Depository Trust
Company (DTC) eligible. DTC is a subsidiary of the Depository Trust
& Clearing Corporation, a U.S. company that manages the
electronic clearing and settlement of publicly traded companies.
DTC services provide simplification, convenience, and cost benefits
for investors and brokers trading Canadian securities in the United
States.
“Our programs have implications worldwide, including our
recently announced U.S. expansion of the Phase 2 trial evaluating
favipiravir as a prophylaxis against COVID-19,” said Kimberly
Stephens, Chief Financial Officer of Appili Therapeutics. “DTC
eligibility provides access to a broader base of investors in North
America and bolsters the visibility of Appili in the capital
markets, thereby further solidifying our ability to improve our
share liquidity and advance our programs.”
Appili’s common shares will continue to trade under Cusip
#03783R107 and ISIN # CA03783R1073.
About Appili Therapeutics
Appili Therapeutics Inc. was founded to advance the global fight
against infectious disease by matching clearly defined patient
needs with drug development programs that provide solutions to
existing challenges patients, doctors, and society face in this
critical disease space. Appili has built a pipeline of assets
designed to address a broad range of significant unmet medical
needs in the infectious disease landscape. This diverse pipeline
aims to address some of the most urgent threats in global public
health, including ATI-2307, a novel, broad spectrum, clinical-stage
antifungal candidate in development for severe and
difficult-to-treat invasive fungal infections; ATI-1701, a vaccine
candidate for tularemia, a very serious biological weapons threat;
ATI-1503, a drug discovery program aimed at generating a novel
class of antibiotics with broad-spectrum activity against
Gram-negative superbugs; and ATI-1501, which employs Appili’s
proprietary, taste-masked, oral-suspension technology with
metronidazole for the growing number of patients with difficulty
swallowing. In addition, the Company is also testing FFTC’s drug
favipiravir for the prevention of COVID-19 as a potential
prophylaxis treatment. Headquartered in Halifax, Nova Scotia, with
offices in Toronto, Ontario, Appili is pursuing worldwide
opportunities in collaboration with scientific and industry
commercial partners, governments and government agencies. For more
information, visit www.AppiliTherapeutics.com.
This news release contains “forward-looking statements” which
reflect the current expectations of the Company’s management future
growth, results of operations, performance and business prospects
and opportunities. Wherever possible, words such as “may,” “would,”
“could,” “should,” “will,” “anticipate,” “believe,” “plan,”
“expect,” “intend,” “estimate,” “potential for,” and similar
expressions have been used to identify these forward-looking
statements. Forward-looking statements involve significant known
and unknown risks, uncertainties and assumptions, including,
without limitation, those listed in the annual information form of
the Company dated June 24, 2020 and the other filings made by the
Company with the Canadian securities regulatory authorities (which
may be viewed at www.sedar.com). Should one or more of these risks
or uncertainties materialize or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. The Company disclaims any intention or
obligation to revise forward-looking statements whether as a result
of new information, future developments or otherwise, except as
required by law.
Neither the TSX Venture Exchange, nor its regulation services
provider (as that term is defined in the policies of the exchange),
accepts responsibility for the adequacy or accuracy of this
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200811005531/en/
Media Contact: Andrea Cohen Sam Brown Inc. T:
917-209-7163 E: andreacohen@sambrown.com
Investor Relations Contact: Kimberly Stephens, CFO Appili
Therapeutics TSXV: APLI E: Info@AppiliTherapeutics.com
Appili Therapeutics (TSXV:APLI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Appili Therapeutics (TSXV:APLI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024